Pharmaceutical Era

Search your requirement

  • Home
  • Press Releases
    • Submit Release
  • Events
  • Reach Us

Social media

Pharmaceutical Era Pharmaceutical Era
  • Home
  • Press Releases
    • Submit Release
  • Events
  • Reach Us
MilliporeSigma receives the industry
MilliporeSigma receives the industry's first EXCiPACT certification for cell culture media manufacturing
Ibex Medical Analytics achieves notable milestones with its AI-first approach to cancer diagnostics
Ibex Medical Analytics achieves notable milestones with its AI-first approach to cancer diagnostics
Albertsons Companies pharmacies now offer COVID and flu vaccines to help protect communities this respiratory virus season
Albertsons Companies pharmacies now offer COVID and flu vaccines to help protect communities this respiratory virus season
OmniSYS rebrands as XiFin Pharmacy Solutions, launches Pharmacy Payor Rate Transparency Monitor, and earns the Pharmacy 500 Award
OmniSYS rebrands as XiFin Pharmacy Solutions, launches Pharmacy Payor Rate Transparency Monitor, and earns the Pharmacy 500 Award
Gilead’s Livdelzi (Seladelpar) receives FDA accelerated approval for primary biliary cholangitis
Gilead’s Livdelzi (Seladelpar) receives FDA accelerated approval for primary biliary cholangitis
ProJenX announces the formation of its Clinical Advisory Board
ProJenX announces the formation of its Clinical Advisory Board
Citius Pharmaceuticals
Citius Pharmaceuticals' LYMPHIR™ wins FDA approval for relapsed/refractory cutaneous T-cell lymphoma
NewAmsterdam Pharma announces positive topline data from the Phase 3 BROOKLYN trial of Obicetrapib in heterozygous familial hypercholesterolemia patients
NewAmsterdam Pharma announces positive topline data from the Phase 3 BROOKLYN trial of Obicetrapib in heterozygous familial hypercholesterolemia patients
Cygnus Technologies and TriLink BioTechnologies® collaborate to launch AccuRes™ Host Cell DNA Quantification Kits
Cygnus Technologies and TriLink BioTechnologies® collaborate to launch AccuRes™ Host Cell DNA Quantification Kits
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules.
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules.
Updated flu and COVID-19 vaccinations are now available at CVS Pharmacy® and MinuteClinic
Updated flu and COVID-19 vaccinations are now available at CVS Pharmacy® and MinuteClinic
FDA Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Relapsed or Refractory Follicular Lymphoma
FDA Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Relapsed or Refractory Follicular Lymphoma

Featured Press Releases

Izalontamab Brengitecan Receives FDA Breakthrough Therapy Designation for Advanced EGFR-Mutated NSCLC

Izalontamab Brengitecan Receives FDA Breakthrough Therapy Designation for Advanced EGFR-Mutated NSCLC

  • By SystImmune, Inc.
  • SystImmune, Inc.
  • 18 Aug 2025
New Survey Shows Pediatricians Strongly Prefer Genexa’s Ingredients Over Leading Children’s Tylenol® Products

New Survey Shows Pediatricians Strongly Prefer Genexa’s Ingredients Over Leading Children’s Tylenol® Products

  • By Genexa
  • Genexa
  • 15 Aug 2025
Proving the strength of its drug-delivery platform, the Daewoong Therapeutics Microneedle Patch achieves best-in-class bioavailability

Proving the strength of its drug-delivery platform, the Daewoong Therapeutics Microneedle Patch achieves best-in-class bioavailability

  • By Daewoong Therapeutics Inc
  • Daewoong Therapeutics Inc
  • 13 Aug 2025
Abcentra LLC Commences Phase 2b

Abcentra LLC Commences Phase 2b 'FORTIFY' Trial with First Patient Dosed, Evaluating Orticumab for Cardiovascular Disease

  • By Abcentra
  • Abcentra
  • 12 Aug 2025
Viatris announces the approval of the first generic iron sucrose injection in the U.S

Viatris announces the approval of the first generic iron sucrose injection in the U.S

  • By Viatris Inc.
  • Viatris Inc.
  • 11 Aug 2025
To advance gene therapy development and manufacturing, ProBio has launched GMP AAV manufacturing services at its Hopewell facility

To advance gene therapy development and manufacturing, ProBio has launched GMP AAV manufacturing services at its Hopewell facility

  • By Probio
  • Probio
  • 11 Aug 2025
Log in
Show
  • Create an account
  • Forgot your username?
  • Forgot your password?
  • 2nd International Conference on Stem Cells and Regenerative Medicine 2025
    Pharmaceutical
    2nd International Conference on Stem Cells and Regenerative Medicine 2025
    10 Nov 2025 10:00 am - 11 Nov 2025 5:30 pm
    USA
  •  2nd International Conference on Immunology & Vaccination 2025
    Pharmaceutical
    2nd International Conference on Immunology & Vaccination 2025
    10 Nov 2025 10:00 am - 12 Nov 2025 5:30 pm
    Paris

Most Popular

  • Osteo Bi-Flex® Adds Plant-Based Omega-3s to Promote Whole Body Health and Wellness
    Osteo Bi-Flex® Adds Plant-Based Omega-3s to Promote Whole Body Health and Wellness
    By Osteo Bi-Flex
    May 19
  • BioLineRx Unveils Poster Presentation on Economic Model Data for APHEXDA® in CD34+ Hematopoietic Stem Cell Mobilization
    BioLineRx Unveils Poster Presentation on Economic Model Data for APHEXDA® in CD34+ Hematopoietic Stem Cell Mobilization
    By BioLineRx
    May 06
  • Leqembi® has received approval for intravenous maintenance treatment in China
    Leqembi® has received approval for intravenous maintenance treatment in China
    By BioArctic AB
    Sep 29
October   2025
M T W T F S S
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    

User Area

  • Login page
  • Registration
  • Edit Profile
  • Forgot Password

Discover

  • About Us
  • Terms Of Use
  • Privacy Policy
  • FAQs

Engage with Us

  • Search on Site
  • Post Press Release
  • Promote Brand
  • List Your Event

Subscribe for e-Newsletter Monthly

Subscribe to the Pharmaceutical Era newsletter to receive timely updates from your favorite products.
loader
Antispam refresh
© 2024 Pharmaceutical Era — A product of HISSM. All Rights Reserved.
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. To find out more, please click here.